Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Co.'s product candidate, ensifentrine, is an inhaled, dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes. Co. is developing ensifentrine in three formulations for the inhalation devices: nebulizer, dry powder inhaler and pressurized metered-dose inhaler. We show 1 historical shares outstanding datapoints in our coverage of VRNA's shares outstanding history.
Understanding the changing numbers of VRNA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VRNA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VRNA by allowing them to research VRNA shares outstanding history
as well as any other stock in our coverage universe. |
Free VRNA Email Alerts:
Video: Shares Outstanding Importance
